Evidence map›Paper›PMID 39981749›Full record

ArticleACS chemical neuroscience2025

Discovery of ONO-2920632 (VU6011887): A Highly Selective and CNS Penetrant TREK-2 (TWIK-Related K+ Channel 2) Preferring Activator

Kentaro Yashiro, Yuzo Iwaki, Hirohito Urata, Masaya Kokubo, Takahiro Mori, Yoko Sekioka, Koichi Isami, Junya Kato, Joshua Wieting, Kevin M McGowan and 6 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS chemical neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Kentaro YashiroDrug Discovery Chemistry, Ono Pharmaceutical Co., Ltd, 3-1-1 Sakurai, Shimamoto, Mishima, Osaka 618-8585, Japan.
Yuzo IwakiDrug Discovery Chemistry, Ono Pharmaceutical Co., Ltd, 3-1-1 Sakurai, Shimamoto, Mishima, Osaka 618-8585, Japan.
Hirohito UrataDrug Discovery Chemistry, Ono Pharmaceutical Co., Ltd, 3-1-1 Sakurai, Shimamoto, Mishima, Osaka 618-8585, Japan.
Masaya KokuboDrug Discovery Chemistry, Ono Pharmaceutical Co., Ltd, 3-1-1 Sakurai, Shimamoto, Mishima, Osaka 618-8585, Japan.
Takahiro MoriResearch Center of Neurology, Ono Pharmaceutical Co., Ltd, 3-1-1 Sakurai, Shimamoto, Mishima, Osaka 618-8585, Japan.
Yoko SekiokaResearch Center of Neurology, Ono Pharmaceutical Co., Ltd, 3-1-1 Sakurai, Shimamoto, Mishima, Osaka 618-8585, Japan.
Koichi IsamiResearch Center of Neurology, Ono Pharmaceutical Co., Ltd, 3-1-1 Sakurai, Shimamoto, Mishima, Osaka 618-8585, Japan.
Junya KatoPharmacokinetic Research, Ono Pharmaceutical Co., Ltd, 3-1-1 Sakurai, Shimamoto, Mishima, Osaka 618-8585, Japan.
Joshua WietingWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Kevin M McGowanWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Thomas M BridgesWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Olivier BoutaudWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Darren W EngersWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Jerod S DentonDepartment of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States.
Haruto KurataDrug Discovery Chemistry, Ono Pharmaceutical Co., Ltd, 3-1-1 Sakurai, Shimamoto, Mishima, Osaka 618-8585, Japan.ORCID 0000-0002-9009-3428
Craig W LindsleyWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.ORCID 0000-0003-0168-1445

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Herein we describe our initial work on the K

Indexed as

AnalgesicsCentral Nervous SystemPotassium Channels, Tandem Pore DomainAnimalsCricetulusDose-Response Relationship, DrugDrug DiscoveryHEK293 CellsHigh-Throughput Screening AssaysHumansMaleMiceRatsAnalgesicspotassium channel protein TREK-1Potassium Channels, Tandem Pore Domainion channelK2P (two-pore domain potassium channel)painTREK (TWIK-Related K+ Channel)

Identifiers

PMID39981749
PMCPMC11887051

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.